AdoRx Therapeutics is actively involved in the exploration of novel treatments for cancer by influencing the adenosine pathway. Elevated adenosine levels within the tumor microenvironment facilitate immune system evasion by cancer cells. The primary focus of AdoRx's developmental initiatives revolves around the creation of specific adenosine receptor antagonists tailored to counteract the impact of heightened adenosine levels. Based in the UK, AdoRx Therapeutics is a pharmaceutical research firm that has secured financial support from Epidarex Capital and Sixth Element Capital. The distinguished leadership team at AdoRx has contributed to the discovery of over 25 potential clinical candidates and collectively possesses more than 60 years of experience.